Targeting TRAIL |
| |
Authors: | George Nicolae Daniel Ion George Mihai Nitulescu Costin Ioan Popescu |
| |
Institution: | 1. Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, Bucharest 020956, Romania;2. Institute of Biochemistry of the Romanian Academy, Splaiul Independentei 296, Bucharest 600031, Romania |
| |
Abstract: | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, has been investigated in the past decade for its promising anticancer activity due to its ability to selectively induce apoptosis in tumoral cells by binding to TRAIL receptors (TRAIL-R). Macromolecules such as agonistic monoclonal antibodies and recombinant TRAIL have not proven efficacious in clinical studies, therefore several small molecules acting as TRAIL-R agonists are emerging in the scientific literature. In this work we focus on systemizing these drug molecules described in the past years, in order to better understand and predict the requirements for a novel anti-tumoral therapy based on the TRAIL-R-induced apoptotic mechanism. |
| |
Keywords: | Corresponding author TRAIL Apoptosis Cancer Death receptor Anti-tumoral |
本文献已被 ScienceDirect 等数据库收录! |
|